Systemic Effects After Local Injection of Platelet-rich Plasma

Not Applicable

Completed

• Conditions: Platelet Rich Plasma (PRP)
• Interventions: Other: saline injection; Other: platelet rich plasma

• Registration Number: NCT04456907
• Lead Sponsor: Chang Gung Memorial Hospital

Brief Summary

Objective Platelet-rich plasma (PRP) is widely utilized in the treatment of sports injuries with favorable outcomes. However, potential systemic effects after localized PRP injection are unclear at present.

Design: prospective randomized study Methods Twenty-four Taiwanese male athletes with tendinopathy were randomized into a PRP group (n = 13) or a saline group (n = 11).

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-03
• Study Start: 2017-09-22
• Primary Completion: 2017-11-21
• Study Completion: 2018-03-28
• Study First Submitted: 2020-06-02
• Study First Submitted QC: 2020-06-29
• Last Update Submitted: 2020-06-29
• Study First Posted: 2020-07-07
• Last Update Posted: 2020-07-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 24

Inclusion Criteria

Not provided

Exclusion Criteria

• Receive local injections and surgery within three months
• Systemic disease
• Diagnosis of anemia

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Saline group	saline injection	Receive saline injection
PPR group	platelet rich plasma	Receive PRP injection

Primary Outcome Measures

Name	Time	Method
Urinary excretion of endogenous AAS metabolites	1 week	Doping substances in urine, mainly metabolites of anabolic androgenic steroids (AAS), were quantified, including testosterone (17β-hydroxyandrost-4-en-3-one), epitestosterone (17α- hydroxy-4-androsten-3-one), androsterone (4-androsten-3,17-dione), etiocholanolone (3α-hydroxy-5β-androstan-17-one), DHEA (dehydroepiandrosterone), dihydroandrosterone (5α- androstane-3α,17β-diol), and etiocholane-3α,17β-diol (5β -androstane-3α,17β-diol). Each urine sample (6 mL) was mixed with 50 μL standard solution and 1 mL phosphate buffer, and the mixture was heated for 60 min at 50°C. After cooling at room temperature, liquid-liquid extraction was performed, and phase separation was achieved. The organic extract was evaporated to dryness, and the dried residue was further derivatized with 50 μL of MSTFA solution for 30 min at 60°C. Finally, the sample was subjected to gas chromatographic analysis and mass spectrometric analysis for quantification of doping substances of interest.

Trial Locations

Locations (1)

Chang Gung Medical Hosptial; 🇨🇳 Kaohsiung, Taiwan